Candesartan

Candesartan is an ARB (angiotensin II receptor blocker), a medicine taken by mouth. The US label read, for ATACAND tablets (candesartan cilexetil), lists two uses: treating high blood pressure in adults and in children 1 to under 17 years of age, and treating heart failure (NYHA class II-IV), where the label says it reduces cardiovascular death and heart failure hospitalization. Atacand is the brand name on the label read.

Also called Atacand · Candesartan cilexetil

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 214354; UNII R85M2X0D68. The label names the substance as candesartan cilexetil, a prodrug that the label says is hydrolyzed to candesartan, so UNII R85M2X0D68 is the UNII of the cilexetil ester and is a broad match. MeSH has no descriptor for candesartan; C077793 is the MeSH supplementary concept record for candesartan cilexetil, also a broad match. Class: Angiotensin 2 Receptor Blocker (FDA established pharmacologic class, RxClass). The label read is the ANI Pharmaceuticals, Inc. label for ATACAND (candesartan cilexetil) tablets, application NDA020838, effective 2025-12-22 in openFDA; Drugs@FDA lists the application's sponsor as ANI PHARMS. Generic candesartan labels and the ATACAND HCT combination label were not read. This page records label indications and the class only: no trial result and no dose is given.

Trials at a glance

The figures count the 8 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
8
Phase 3 or 4
5
Recruiting
1
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseRecruitingCompletedUnknown statusAll statuses
Phase 20303
Phase 31102
Phase 40213
All phases1618

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

And 3 more.

About this drug

Level
Substance
Mechanism
Not reported

Classification codes

  • UNII R85M2X0D68
  • MeSH read 2026-11-09 C077793

Claims and evidence

Context Children for whom the US label of candesartan (Atacand) lists hypertension as an indication: children 1 to under 17 years of age

Recipient
Child
Population
Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Label wording: children 1 to under 17 years of age
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Children with hypertension (children 1 to under 17 years of age)
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of ATACAND (candesartan cilexetil) tablets, in the ANI Pharmaceuticals, Inc. version dated 2025-12-22 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure, in children 1 to under 17 years of age.

    Applies to Child Children for whom the US label of candesartan (Atacand) lists hypertension as an indication: children 1 to under 17 years of age

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for ATACAND (candesartan cilexetil) tablets, ANI Pharmaceuticals, Inc. label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 94a59260-d2b6-464a-b5b9-bbc599e57e10 (manufacturer ANI Pharmaceuticals, Inc., application NDA020838), returned on 2026-11-09. The label text is dated 2025-12-22 (effective_time). Other openFDA records of candesartan labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      The label sentence that names children in the hypertension indication, quoted in the research quote table.
      Retrieved
      Source effective date
      2025-12-22
      Source state
      Current
      Version fingerprint
      6e366d099c851afcac0f711669c077763a34505dc03331674c97f4d2f3593f5a
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for ATACAND (candesartan cilexetil) tablets, ANI Pharmaceuticals, Inc. label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 94a59260-d2b6-464a-b5b9-bbc599e57e10 (manufacturer ANI Pharmaceuticals, Inc., application NDA020838), returned on 2026-11-09. The label text is dated 2025-12-22 (effective_time). Other openFDA records of candesartan labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20251222.
      Retrieved
      Source effective date
      2025-12-22
      Source state
      Current
      Version fingerprint
      6e366d099c851afcac0f711669c077763a34505dc03331674c97f4d2f3593f5a
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Context Patients for whom the US label of candesartan (Atacand) lists an indication: adult hypertension, NYHA class II-IV heart failure

Recipient
Recipient not specified
Population
Patients described in the indications section of the label. The hypertension indication names adults (and, separately, children 1 to under 17 years of age); the heart failure indication does not state an age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Adults for hypertension, as the passage read states; not stated for heart failure
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
Included
  • Adult patients with hypertension
  • Patients with heart failure (NYHA class II-IV)
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of ATACAND (candesartan cilexetil) tablets, in the ANI Pharmaceuticals, Inc. version dated 2025-12-22 in openFDA, lists the medicine for the treatment of hypertension in adults, to lower blood pressure (the same label sentence also names children 1 to under 17 years of age, recorded separately); and for the treatment of heart failure (NYHA class II-IV), with the label stating that the medicine reduces cardiovascular death and heart failure hospitalization.

    Applies to Recipient not specified Patients for whom the US label of candesartan (Atacand) lists an indication: adult hypertension, NYHA class II-IV heart failure

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Supports openFDA drug label record for ATACAND (candesartan cilexetil) tablets, ANI Pharmaceuticals, Inc. label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 94a59260-d2b6-464a-b5b9-bbc599e57e10 (manufacturer ANI Pharmaceuticals, Inc., application NDA020838), returned on 2026-11-09. The label text is dated 2025-12-22 (effective_time). Other openFDA records of candesartan labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      The label sentences that give the indications named in the statement, each quoted in the research quote table.
      Retrieved
      Source effective date
      2025-12-22
      Source state
      Current
      Version fingerprint
      6e366d099c851afcac0f711669c077763a34505dc03331674c97f4d2f3593f5a
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for ATACAND (candesartan cilexetil) tablets, ANI Pharmaceuticals, Inc. label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 94a59260-d2b6-464a-b5b9-bbc599e57e10 (manufacturer ANI Pharmaceuticals, Inc., application NDA020838), returned on 2026-11-09. The label text is dated 2025-12-22 (effective_time). Other openFDA records of candesartan labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20251222.
      Retrieved
      Source effective date
      2025-12-22
      Source state
      Current
      Version fingerprint
      6e366d099c851afcac0f711669c077763a34505dc03331674c97f4d2f3593f5a
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Background openFDA Drugs@FDA record for application NDA020838 (ATACAND, sponsor ANI PHARMS): product and sponsor

      Regulator · U.S. Food and Drug Administration (openFDA, Drugs@FDA) · Edition The openFDA Drugs@FDA record for application NDA020838, returned on 2026-11-09. It lists the sponsor and the products of the application; only the first product listing is quoted.

      Locator
      results[0].products[0].brand_name
      How it applies
      Drugs@FDA product listing for application NDA020838, which confirms the product the label belongs to.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      ec1683f25cf3821591331aea65021120395a52d28829ac5fc903c50d651cbef8
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short values are quoted. The raw record is committed in the atlas repository.

Pregnancy, lactation and children

The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.

In newborns, infants and children 1

Claims whose context is a newborn, an infant or a child.

  • Description Evidence stage not applicable Certainty not assessed

    The US label of ATACAND (candesartan cilexetil) tablets, in the ANI Pharmaceuticals, Inc. version dated 2025-12-22 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure, in children 1 to under 17 years of age.

    Applies to Child Children for whom the US label of candesartan (Atacand) lists hypertension as an indication: children 1 to under 17 years of age

    Population, setting and follow-up
    • Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.
    • Prescription medicine, as described in the US label
    • United States (label of the US Food and Drug Administration)
    • Label wording: children 1 to under 17 years of age
    • Gestational age Not reported
    • Postnatal age Not reported
    Follow-up Not applicable (label statement)
    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for ATACAND (candesartan cilexetil) tablets, ANI Pharmaceuticals, Inc. label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 94a59260-d2b6-464a-b5b9-bbc599e57e10 (manufacturer ANI Pharmaceuticals, Inc., application NDA020838), returned on 2026-11-09. The label text is dated 2025-12-22 (effective_time). Other openFDA records of candesartan labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      The label sentence that names children in the hypertension indication, quoted in the research quote table.
      Retrieved
      Source effective date
      2025-12-22
      Source state
      Current
      Version fingerprint
      6e366d099c851afcac0f711669c077763a34505dc03331674c97f4d2f3593f5a
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for ATACAND (candesartan cilexetil) tablets, ANI Pharmaceuticals, Inc. label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 94a59260-d2b6-464a-b5b9-bbc599e57e10 (manufacturer ANI Pharmaceuticals, Inc., application NDA020838), returned on 2026-11-09. The label text is dated 2025-12-22 (effective_time). Other openFDA records of candesartan labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20251222.
      Retrieved
      Source effective date
      2025-12-22
      Source state
      Current
      Version fingerprint
      6e366d099c851afcac0f711669c077763a34505dc03331674c97f4d2f3593f5a
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

ATACAND

No label from the application holder was found in the openFDA label dataset for application NDA020838. This page does not show another labeler's label in its place.

ATACAND HCT

No label from the application holder was found in the openFDA label dataset for application NDA021093. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA020838 ATACAND
  2. Approval NDA021093 ATACAND HCT
  3. Supplemental approval NDA020838 ATACAND
  4. Supplemental approval NDA020838 ATACAND
  5. Supplemental approval NDA020838 ATACAND
  6. Supplemental approval NDA020838 ATACAND

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 2

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 4 efficacy supplement approvals on record.

    ProductNDA020838

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA021093

Registry trials 8

Record details

Record id
cardio:candesartan
Content hash
2731a12b2f9c4c04b600b2872d010a8589c82f9aeffb9935a0b52ba638fba0a2